[Arterial vasospasm as a complication of the prevention of thromboembolism with heparin-dihydroergotamine and its treatment].
D000293:Adolescent; D000328:Adult; D004087:Dihydroergotamine / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005264:Femoral Fractures / Q000601:surgery*; D005528:Foot / Q000098:blood supply*; D005593:Fracture Fixation, Internal; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D007511:Ischemia / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D005996:Nitroglycerin / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D013035:Spasm / Q000139:chemically induced; D013924:Thrombophlebitis / Q000517:prevention & control*; D013978:Tibial Fractures / Q000601:surgery*
D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; C031388:heparin-dihydergot; D004087:Dihydroergotamine; D006493:Heparin; D005996:Nitroglycerin
Arterieller Vasospasmus als Komplikation der Thromboembolieprophylaxe mit Heparin-Dihydroergotamin und seine Behandlung.